

Under the Paperwork Reduction Act of 1996 no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitution for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known Application Number: 10/823,506 Filing Date: April 12, 2004 First Named Inventor: Carl G. Hellerqvist Group Art Unit: Not yet assigned 1646 Examiner Name: Not yet assigned Ruixiang Li Attorney Docket Number: 22100-0202 (49530-299673)	
Sheet	1	of	3		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/823,506		
		Filing Date	April 12, 2004		
		First Named Inventor	Carl G. Hellerqvist		
		Group Art Unit	Not yet assigned 1646		
		Examiner Name	Not yet assigned Ruixiang Li		
Sheet		of		Attorney Docket Number	22100-0202 (49530-299673)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RLi	13	DEVORE <i>et al.</i> , "Phase I Study of the Antineovascularization Drug CM101," <i>Clinical Cancer Research</i> , Vol. 3, pp. 365-372 (1997)	
	14	FU, <i>et al.</i> , "Expressional Cloning of CM101 Receptor Gene from Mammalian Cells," <i>Proceedings of the American Association of Cancer Research</i> , Abstract No. 3677, Vol. 40, p. 557 (1999)	
	15	GEARING, <i>et al.</i> , "Expression Cloning of a Receptor for Human Granulocyte-Macrophage Colony-Stimulating Factor," <i>The EMBO Journal</i> , Vol. 8, No. 12, pp. 3667-3676 (1989)	
	16	HELLERQVIST <i>et al.</i> , "Anti-Tumor Effects of GBS Toxin are Caused by Induction of a Targeted Inflammatory Reaction," <i>Angiogenesis: Molecular Biology, Clinical Aspects</i> , Edited by Maragoudakis <i>et al.</i> , Plenum Press, New York, pp. 265-269 (1994)	
	17	HELLERQVIST <i>et al.</i> , "Antitumor Effects of GBS Toxin: A Polysaccharide Exotoxin From Group B β -Hemolytic Streptococcus," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 120, pp. 63-70 (1993)	
	18	HELLERQVIST <i>et al.</i> , "Molecular Basis for Group B β -Hemolytic Streptococcal Disease," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, pp.51-55 (1987)	
	19	HELLERQVIST <i>et al.</i> , "Preliminary Results of a Phase I Trial of CM101 in Cancer Patients," <i>J. Cellular Biochemistry</i> , Suppl. 19B, p. 26 (1995)	
	20	HELLERQVIST <i>et al.</i> , "Studies on Group B β -Hemolytic Streptococcus. I. Isolation and Partial Characterization of an Extracellular Toxin," <i>Pediatr. Res.</i> , Vol. 15, pp. 892-898 (1981)	
	21	HILLIER, <i>et al.</i> , "zr59d01.rl Soares NhMPu S1 Homo sapiens cDNA clone 667681 5' Similar to Tr:G507415 G507415 Brain Specific Na ⁺ -Dependent Inorganic Phosphate Cotransporter," Database EMBL - EMBEST20 'Online!, Entry HS1173506, Acc. No. AA258513 (March 19, 1997)	
	22	KOVACS <i>et al.</i> , "Fibrogenic Cytokines and Connective Tissue Production," <i>The FASEB Journal</i> , Vol. 8, pp. 854-861 (1994)	
	23	NORRBY, "Angiogenesis: New Aspects Relating to Its Initiation and Control," <i>APMIS</i> , Vol. 105, pp. 417-437 (1997)	
RLi	24	POLVERINI, "The Pathophysiology of Angiogenesis," <i>Crit. Rev. Oral. Biol. Med.</i> , Vol. 6, No. 3, pp.230-247 (1995)	

Examiner Signature	Ruixiang Li	Date Considered	7/17/2006
--------------------	-------------	-----------------	-----------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/823,506		
		Filing Date	April 12, 2004		
		First Named Inventor	Carl G. Hellerqvist		
		Group Art Unit	Not yet assigned 1646		
		Examiner Name	Not yet assigned Ruixiang Li		
Sheet		of		Attorney Docket Number	22100-0202 (49530-299673)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RLi	25	QUINN, <i>et al.</i> , "CM101, A Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 121, pp.253-256 (1995)	
RLi	26	THURMAN, <i>et al.</i> , "Actue Inflammatory Changes in Subcutaneous Microtumors in the Ears of Mice Induced by Intravenous CM101 (GBS Toxin)," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 122, pp. 549-553 (1996)	
RLi	27	WAMIL, <i>et al.</i> , "Soluble E-Selectin in Cancer Patients as a Maker of the Therapeutic Efficacy of CM101, a Tumor-Inhibiting Anti-Neovascularization Agent, Elevated in Phase I Clinical Trail," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 123, pp. 173-179 (1997)	

Examiner Signature	Ruixiang Li	Date Considered	7/17/2006
-----------------------	-------------	--------------------	-----------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.